rdmirza

We’ve had a bunch of folks express interest (thanks!)..

But to be clear: this is an in person (Toronto) / remote hybrid position.

If your CV doesn’t have a locale, please confirm your willingness to come in person/relocate

*Strello Health | Founding Software Engineer | Full-time | Hybrid Remote | Toronto/GTA*

Strello Health builds AI voice agents for healthcare. We’re post-seed, generating revenue, and scaling quickly.

You’ll work directly with the founders to build the core infrastructure behind real-time voice conversations, including audio streaming, LLM orchestration, APIs, integrations, observability, and production systems.

We’re looking for engineers with experience in backend or platform development, distributed systems, APIs, Linux, and building reliable systems from 0→1. Co-op experience counts, and we’re hiring across experience levels.

Bonus: WebRTC/WebSockets, ML or LLM infrastructure, Node.js/TypeScript, Python, Docker, Kubernetes, or open-source contributions.

Tech stack: TypeScript/Node.js and Python.

Email: [email protected]

Aye. Outside edit window unfortunately

Two familial cases of sudden cardiac death? That’s not normal. That’s an indication to investigate.

Your take on Evidence Based Medicine (EBM) is wrong.

At the top of the evidence hierarchy is N-of-1 trials (and below that are high quality meta-analyses of trials). Nothing is more informative about treatment response in a person than testing it in that person. This is the heart of personalized medicine, and exactly for the reason you stated: Different interventions work differently for different people.

And any practitioner worth their salt is unsurprised by this headline. A great example is that illness and inflammation increase insulin resistance via counter-regulatory hormones.

You got one thing right, intuition often turns out to be wrong. That is why the vast majority experimental therapeutics built on great ideas never get passed initial testing.

My immediate thought. Big Claims without backing.

Your model makes predictions. Prove they’re worth salt.

At that point you’d simply cut out the tumor.

Small individual study sample size does not necessarily mean junk. Junk is a product of poor methodology. The main concern with sample sizes may be overestimates of effects if the event is rare, or poor precision (ie large confidence intervals).

However you’re right to presume that small studies are likely to be lower quality, often because they’r observational as opposed to randomized studies.

I think you’re spot on about the clear advantage of your approach relative to the article and blood biopsies: If you’re looking for cancer in the blood, you’re probably too late as this suggests metastatic spread.

You suggest something better: look for tissue level markers.

The immunotherapy revolution (ie CTLA/PD1 molecules), you’ll recognize that leveraging the immune system is brilliantly effective.

Presumably stealth genes do not evolve first, but rather proliferative genes. And this is why any chronic damage triggers cancer because renewal is a replicative process, and replications begets copy errors. wanderers and passersby will have to recognize I’m simplifying.

I have a great lateral. Not sure if you have the funds to try two things, but TCR characterization is a wonderful idea. At least thats the best way to do it, as I see it. has many application beyond cancer

Good luck!

Even better is installing an implantable cardiac defibrillator (ICD) in those at high risk.

The main concern here (and most observational studies) is confounding by indication. Specifically, the same reason some people got hydroxychloroquine as opposed methotrexate is the same reason you see differences in the outcome. In this case there’s plausible confounding that needs to be addressed before any conclusion like the title could be drawn.

Generally hydroxychloroquine is used in mild rheumatoid, whereas methotrexate is used in moderate-severe disease.

Inflammation in rheumatoid (and other inflammatory diseases) contribute to atherosclerosis and plaque buildup. Rheumatoid increases the risk of coronary disease by 1.5-2x.

That difference alone could account for the difference in dementia, particularly vascular dementia.

I'm intrigued about your research and would love to hear more. I'm a physician interested the effect of for-profit care on health care and outcomes.

As an example, we showed that for-profit dialysis facilities in the US have about a 7% higher mortality rate. We did a meta-analysis and every study barring one found higher mortality in for-profit dialysis facilities. Other studies suggest one reason is lower referral rates for kidney transplantation. Higher mortality has also been shown in for profit hospitals.

Yes cholesterol is a vital building block. However the medical literature consistently shows a strong relationship between LDL and non-HDL cholesterol levels and heart attack and stroke.

Various cholesterol lowering drugs, statins being the most widely prescribed but certainly not the only class, show consistent relationship with cholesterol lowering and reduced risk of MACE (MI, stroke).

Plaque is made of foam cells that consume cholesterol. They grow and obstruct arteries, and eventually rupture causing critical flow obstructing events.